- €4.70bn
- €5.70bn
- €5.53bn
- 76
- 64
- 43
- 67
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 3,547 | 3,740 | 3,935 | 5,074 | 5,532 |
Cost of Revenue | |||||
Gross Profit | 859 | 896 | 992 | 1,264 | 1,429 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 3,266 | 3,421 | 3,536 | 4,638 | 5,025 |
Operating Profit | 281 | 319 | 399 | 436 | 507 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 269 | 307 | 395 | 431 | 473 |
Provision for Income Taxes | |||||
Net Income After Taxes | 202 | 232 | 296 | 338 | 359 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 201 | 232 | 295 | 338 | 357 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 201 | 231 | 296 | 338 | 357 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 1.34 | 1.55 | 1.99 | 1.86 | 2 |
Dividends per Share |